Teva Pharma (NYSE: TEVA) reported Q4 EPS of $1.31, in-line with the analyst estimate of $1.31. Revenue for the quarter came in at $5.17 billion versus the consensus estimate of $5.17 billion.

For earnings history and earnings-related data on Teva Pharma (TEVA) click here.